Slingshot members are tracking this event:
Arrowhead Pharmaceuticals (ARWR) Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Top-line data from a single dose of 100 mg of ARO-APOC3 in healthy volunteers demonstrated mean maximal reductions of plasma triglycerides of 63% and APOC3 protein of 94% without serious or severe adverse eventsThe most common adverse events observed to date, all mild or moderate, have been headache, upper respiratory infection and mild injection site findings
Top-line data from a single dose of 200 mg of ARO-ANG3 in healthy volunteers demonstrated mean maximal reductions of plasma triglycerides of 66% and ANGPTL3 protein of 79% without drug-related serious or severe adverse events
The most common adverse events seen to date, all mild or moderate, have been headache and upper respiratory infection
ARO-ANG3 reduced triglycerides and LDL-C in LDL receptor knockout mice
ARO-ANG3 also ameliorates steatosis and improves insulin sensitivity in diet-induced obese mice
In mouse studies, ANGPTL3 has shown endocrine effects on triglyceride and LDL-C metabolism and apparent autocrine effects on hepatic steatosis and insulin sensitivity
Published research also indicates that APOC3 and ANGPTL3 are strong potential targets for addressing cardiovascular diseaseGenetic studies indicate that plasma triglycerides are an independent risk factor for cardiovascular diseaseLoss of function mutations of APOC3 or ANGPTL3 are associated with markedly reduced triglycerides and other lipid parameters without reported adverse phenotype
Slingshot Insights Explained
Sep 16, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Aro-apoc3, Aro-ang3, Rnai